Navigation Links
Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
Date:2/27/2012

BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference being held at the Sheraton Miyako Hotel in Tokyo, Japan.

The TIDES Oligonucleotide and Peptide Conferences are the premier forums focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the growth of peptide therapeutics.

Recent Advances in Routes of Delivery for Peptide Pharmaceuticals

Plenary keynote presentation

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Tuesday, February 28, at 4:30pm JST (Tuesday, February 28, at 2:30am EST)
  • Focus: Peptides in advanced stages of clinical development with oral or transdermal technologies

Clinical Development of a Solid Dosage Oral Formulation for the 32 Amino Acid Peptide Salmon Calcitonin

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Thursday, March 1, at 12:00pm JST (Wednesday, February 29, at 10:00pm EST)
  • Focus: Advantages of Unigene's oral delivery technology demonstrated in a Phase 3 clinical study for salmon calcitonin, including an improved variability profile and limited food effects on the biological activity of the peptide

"I welcome the opportunity to provide the attendees of AsiaTIDES with a comprehensive review of recent advancements in the delivery of peptides, most notably Unigene's validated and most clinically advanced oral peptide delivery technology platform, as well as the company's late-stage and feasibility oral peptide programs developed via our Peptelligence™ platform," said Dr. Mehta. "Advances in the delivery of peptide therapeutics, particularly oral peptide technologies, have the opportunity to redefine the treatment regimen and market for numerous debilitating, chronic conditions.  Given this opportunity, the pharmaceutical industry is directing increasing attention and resources to companies and institutions that are developing next-generation peptide compounds, making a conference like AsiaTIDES an extremely valuable scientific and business development event."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
2. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
3. Unigene Provides 2012 Business Outlook
4. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
5. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
6. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
7. Unigene Reports Third Quarter 2011 Financial Results
8. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
9. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
10. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
11. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):